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382 The Journal of Thoracic and Cardbjective: With the widespread use of computed tomography and the emergence of
creening programs, non–small cell lung cancer is increasingly detected in sizes
cm or less. We sought to examine the long-term survival and recurrence patterns
fter resection of these tumors.
ethods: We conducted a retrospective review over a 15-year period to identify
atients with surgically resected non–small cell lung cancer measuring 1 cm or less.
edical records were reviewed, and survival data were analyzed by the Kaplan-
eier method.
esults: There were 83 patients (26 men, 57 women) with a median age of 67 years
range 43-88 years). Median tumor size was 0.90 cm. Lobectomy was performed in
1 patients, bilobectomy in 1, pneumonectomy in 1, segmentectomy in 5, and wedge
esection in 5. Postoperative stage was IA in 67 patients, IB in 4, IIA in 1, IIB in 4,
IIA in 2, and IIIB in 5. Median follow-up was 31 months. There was 1 operative
eath (1.2%). In 5 (31.3%) of the 16 patients with non-IA disease, recurrent cancer
eveloped after resection. No recurrences were observed in the 67 patients with
tage IA disease. The 5- and 10-year overall survivals for the entire cohort were
6% and 72%, respectively, and the disease-specific survival was 91% at both
ime points. For patients with stage IA disease, 5- and 10-year survivals were
4% and 75%, respectively, and the disease-specific survival was 100% at both
ime points.
onclusion: Eighty-one percent of patients with resected non–small cell lung cancer
easuring 1 cm or less had stage IA disease. After surgical resection, recurrence is
are and long-term survival is excellent.
ung cancer is the leading cause of cancer deaths in the United States. In 2005,
an estimated 173,000 Americans were diagnosed with lung cancer, and
164,000 of them will die of their disease.1 The majority of patients with
on–small cell lung cancer (NSCLC) have metastatic or locally advanced disease at
resentation, whereas less than 15% present with stage I disease, in which surgical
esection results in a 5-year survival of 60% to 80%. The improved survival after
urgical resection seen in patients with stage I disease has led to renewed interest in
creening programs for lung cancer with the promise of detecting smaller and
otentially more curable tumors. With the increased prevalence of screening pro-
rams as well as the widespread use of high-resolution computed tomography (CT),
SCLC is more frequently detected in sizes 1 cm or less. However, it is still
ncertain whether detection of smaller tumors translates into improved long-term
urvival. Very few studies have reported the long-term survival and recurrence
atterns after resection of these small lesions. There is also controversy regarding
he optimal surgical approach for these small tumors. In this study, we reviewed our
xperience in patients with resected NSCLC measuring 1 cm or less in size to
iovascular Surgery ● December 2006
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G
TSetermine the overall and disease-specific survival as well
s tumor recurrence after surgical resection.
atients and Methods
atients
e conducted a retrospective review of all patients with NSCLC
n a prospective database to identify patients with pathologic
SCLC measuring 1 cm or less that was surgically resected at our
nstitution from January 1991 to December 2005. Patients who had
eoadjuvant therapies before resection were excluded. A total of
3 patients were identified. Hospital and office records of each
atient were reviewed for demographic and clinical data including
ge, gender, smoking status, preoperative pulmonary functional
ssessment, preoperative radiologic assessment, associated comor-
idities, and clinical stage. Records were also reviewed for peri-
perative and pathologic data, including surgical approach, extent
f resection, 30-day operative mortality (defined as death during
he same hospitalization or within 30 days after the operation),
omplications, length of stay, tumor size, histologic type, patho-
ogic stage, and use of adjuvant therapy. Staging was done accord-
ng to the TNM classification of the American Joint Committee for
ancer Staging and Revised International System for Staging
ung Cancer.2 Follow-up was obtained through office visits and
elephone interviews.
tatistical Analysis
tatistical analysis was performed with SPSS statistical software
SPSS Inc, Chicago, Ill). Overall and disease-specific survival of
he entire cohort and for two subgroups (stage IA group and stage
on-IA group) was analyzed by the Kaplan-Meier method. In this
tudy, overall survival is defined as the percentage of patients who
ave survived for a defined period of time after surgical resection.
isease-specific survival is defined as the percentage of patients
ho have survived lung cancer for a defined period of time after
urgical resection. In calculating this percentage, we counted only
eaths from lung cancer, excluding patients who died of other
auses. The log-rank test was used to determine significance of
urvival distributions among groups. Independent t tests were used for
wo-group comparisons of continuous variables. Categorical data in
ross-tabulation tables were compared by the Fisher exact test or the
earson 2 test. Nonparametric data were analyzed with the Mann-
hitney U test. This study was approved by the Institutional Review
oard of the Weill Medical College of Cornell University.
esults
linical Findings
uring the 15-year study period from January 1991 to
Abbreviations and Acronyms
CI  confidence interval
CT  computed tomography
ELCAP  Early Lung Cancer Action Program
NSCLC non–small cell lung cancer
PET  positron emission tomographyecember 2005, 83 patients were identified (26 men, 57 d
The Journal of Thoracicomen) with a median age of 67 years (range 43-88 years).
he number of NSCLCs 1 cm or less in size increased
teadily over the study period. The numbers of resected
umors were 8, 21, and 54 over the 3 consecutive 5-year
eriods. These represented 3.8%, 5.8%, and 7.0% of the
otal number of surgical resections for NSCLC over the
ame time periods. Seventy-eight patients were smokers and
were never-smokers. Of the smokers, 17 were current and
1 were former smokers. Median pack-years of all smokers
as 40. Seventeen patients had respiratory symptoms at
resentation, which included cough, shortness of breath,
nd fever. The majority of the tumors were discovered
ncidentally by CT or chest radiograph. Tissue diagnoses
ere obtained by CT-guided fine needle aspiration in 48
atients and flexible bronchoscopy in 1 patient. In the re-
aining 34 patients, the diagnosis was suggested by a
ositive result on positron emission tomography (PET)
canning (n  13) or suspicious findings on CT scanning
n  21). Twenty-one patients were enrolled in the Early
ung Cancer Action Project (ELCAP) screening program
nd had their tumors detected by low-dose CT. Pulmonary
unction tests were performed in 70 patients. Mean forced
xpiratory volume in 1 second was 83% of predicted (range
6%-100%). Mean forced vital capacity was 87% of pre-
icted (range 53%-100%). Mean diffusing capacity was
6% of predicted (range 31%-100%).
ET Scanning
ET scanning was obtained preoperatively in 37 patients in
hom a standard uptake value was reported. Twenty-two
atients had a positive finding. The median standard uptake
alue for a positive result was 2.7 g/mL. The histologic
haracteristics for the 22 PET-positive tumors were as
ollows: adenocarcinoma in 17 (mixed subtype of adeno-
arcinoma with bronchoalveolar features in 3, bronchoal-
eolar carcinoma subtype in 2), squamous cell carcinoma in
, and large cell carcinoma in 3. Of 4 patients with patho-
ogic N1 disease, only 1 patient’s nodal disease was PET
ositive preoperatively. One of 2 patients with pathologi-
ally confirmed N2 disease had a preoperative PET scan
hat showed no uptake in the mediastinum. Of the 5 patients
ith intralobar satellite lesions (T4), 3 patients had a pre-
perative PET scan. In all 3 patients the PET scan failed to
dentify the satellite lesions.
urgical Approach and Extent of Resection
ll surgical procedures are listed in Table 1. Eighteen
atients underwent mediastinoscopy. The indications for
ediastinoscopy were lymphadenopathy (1.5 cm on CT)
n 3 patients, central tumor in 2, positive mediastinal uptake
n PET in 2, associated medical comorbidities in 3, and
urgeon preferences in 8. One patient was found to have N2
isease by mediastinoscopy. Lobectomy was the most com-
and Cardiovascular Surgery ● Volume 132, Number 6 1383
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1
G
TSonly performed resection. Bilobectomy was done in 1
atient because of an endobronchial tumor at the bifurcation
f the middle and lower lobe bronchus. In another patient, a
neumonectomy was performed because of a centrally lo-
ated tumor involving the bifurcation of the left upper and
ower lobe bronchus. Limited resections were done in 10
atients (5 segmentectomies, 5 wedge resections). The rea-
ons for limited resection included compromised pulmonary
eserve in 6 patients, prior lobectomy in 1, associated co-
orbidities in 1, and incorrect initial frozen-section diag-
osis in 2. As presented in Table 2, the group with limited
esection had significantly compromised preoperative pul-
onary reserve compared with patients with anatomic resec-
ions. Seventy-four (89%) patients had mediastinal lymph node
issection. All patients had curative R0 resections.
erioperative Course
here was 1 operative death, with an operative mortality of
.2%. This patient died at home of a myocardial infarction
n postoperative day 13. Major complications occurred in 8
atients, with minor complications in 18 patients (Table 3).
he median length of stay in the hospital for the entire
roup was 5 days (range 2-14 days). The median length of
tay in the hospital for the open lobectomy group was 5 days
range 2-14 days) compared with 4 days (range 2-12 days)
ABLE 1. Operative procedures
rocedure type No. of patients Percent
obectomy 71 85.5
Open 58 69.9
Thoracoscopic 13 15.7
ilobectomy 1 1.2
neumonectomy 1 1.2
egmentectomy 5 6.0
edge 5 6.0
Open 3 3.6
Thoracoscopic 2 2.4
0 resection 83 100
ediastinoscopy 18 21.7
Negative 17 20.5
Positive 1 1.2
ediastinal lymph node dissection 74 89.2
ABLE 2. Mean preoperative pulmonary function tests in
atients with limited and anatomic resection
Limited resection Anatomic resection P value
FEV1 65 86 .015
FVC 76 89 .007
DLCO 57 80 .001
EV , Forced expiratory volume in 1 second; FVC, forced vital capacity;1
LCO, diffusing capacity for carbon monoxide. s
384 The Journal of Thoracic and Cardiovascular Surgery ● Decn the thoracoscopic lobectomy group (P  .003 by the
ann-Whitney test).
athologic Findings
istopathologic characteristics of all 83 patients with re-
ected NSCLC measuring 1 cm or less in size are presented
n Table 4. Forty-six percent of tumors were 1 cm in size,
ith 54% smaller than 1 cm in size. Adenocarcinoma was
he predominant histologic type. Of the 21 patients who had
ABLE 3. Postoperative complications
Complications No. of patients
Major
Reintubation 1
Pneumonia 3
Pulmonary embolism 3
Empyema 1
Minor
Arrhythmia 6
Prolonged air leak 10
Urinary tract infection 1
Wound infection 1
ABLE 4. Histopathologic characteristics of all 83 patients
ith resected <1 cm NSCLC
haracteristic n
umor size (cm)
Median 0.90
Range 0.20-1.00
1 cm 45
1 cm 38
istology
Adenocarcinoma 68
Mixed adenoca/bronchoalveolar subtype 25
Bronchoalveolar carcinoma subtype 9
Squamous cell carcinoma 9
Large cell carcinoma 6
athologic stage
T1 N0—IA 67
T2 N0—IB* 4
T1 N1—IIA 1
T2 N1—IIB 3
T3 N0—IIB 1
T1 N2—IIIA 2
T4 N0—IIIB† 5
athologic stage of ELCAP patients
T1 N0—IA 16
T2 N0—IB 2
T1 N2—IIIA 1
T4 N0—IIIB 2
SCLC, non–small cell lung cancer; ELCAP, Early Lung Cancer Action
roject. *All patients had visceral pleura invasion. †All patients had
atellite tumors.
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G
TSheir tumors detected by ELCAP low-dose screening CT,
6% had stage I disease.
djuvant Therapies
ne patient was found to have N2 disease by mediastinos-
opy. This patient subsequently underwent resection fol-
owed by adjuvant chemotherapy and radiotherapy. Four
ther patients were selected to receive adjuvant chemother-
py for postoperative pathologic stages of IB, IIA, IIB, and
IIA. One patient received adjuvant radiotherapy as the sole
odality after resection of NSCLC with N1 metastasis.
verall and Disease-specific Survival
edian follow-up of all patients was 31 months. Nineteen
ercent of patients (n  16) with resected NSCLC measur-
ng 1 cm or less in size had greater than stage IA disease.
ecurrent cancer developed after resection in 5 (31.3%) of
he 16 patients with non-IA disease. Sites of recurrence
Figure 1. Overall survival of 83 patients with NSCLC measuring 1
cm or less after resection. NSCLC, non–small cell lung cancer.
Figure 2. Overall survival of patients with NSCLC measuring 1 cm
or less after resection, subdividing into pathologic IA and non-IApstage. NSCLC, non–small cell lung cancer.
The Journal of Thoracicere mediastinum, contralateral lung, brain, spine, and both
pine and mediastinum in 1 patient each. The single patient
ith isolated mediastinal recurrence underwent surgical re-
ection of the recurrence followed by adjuvant radiotherapy
nd is currently alive without disease recurrence 12 months
fter treatment. No recurrences were observed in the 67
atients with stage IA disease during the follow-up period.
ive- and 10-year overall survival for the entire cohort was
6% (95% confidence interval [CI] 72%-93%) and 72%
95% CI 51%-85%), respectively (Figure 1). Patients were
eparated into stage IA and non-IA groups for survival
omparison (Figure 2). For patients in stage IA, 5- and
0-year overall survivals were 94% (95% CI 79%-98%) and
5% (95% CI 48%-89%), respectively. For those with
on-IA disease, 5- and 10-year overall survival was signif-
cantly decreased to 48% (95% CI 12%-77%) (P  .014).
Lung cancer disease-specific survival was calculated for
he entire cohort. Five- and 10-year disease-specific survival
as 91% (95% CI 78%-97%) at both time points (Figure 3).
or patients with stage IA disease, 5- and 10-year disease-
pecific survival was 100% at both time points (Figure 4).
or those with non-IA disease, 5- and 10-year disease-
pecific survival was significantly decreased to 48% (95%
I 12%-77%) (P  .001).
When overall 5- and 10-year survival was compared
etween patients with limited resection (n  10) and ana-
omic resection (n 73), there was no significant difference
n survival between the two groups (P  .828). Over the
ast 4 years, lobectomies were mainly done by thoraco-
copic approaches. When the thoracoscopic (n  13) and
he open (n  58) groups were compared, there was no
ignificant difference in overall survival (P  .478).
iscussion
he diagnosis of bronchogenic carcinoma carries a dismal
Figure 3. Disease-specific survival of 83 patients with NSCLC
measuring 1 cm or less after resection. NSCLC, non–small cell
lung cancer.rognosis for the majority of patients. The stage of carci-
and Cardiovascular Surgery ● Volume 132, Number 6 1385
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1
G
TSoma at diagnosis remains one of the most important de-
erminants of survival in NSCLC, with earlier-stage patients
aving a better chance of long-term survival.2 For patients
ith resectable stage I disease, 5-year survival can be as high
s 80%.3 Unfortunately, less than 15% of patients present with
tage I disease. The improved survival in patients with stage
disease led to renewed interest in lung cancer screening
rograms with detection of smaller and possibly more cur-
ble tumors. The ultimate goal of lung cancer screening
rograms is to shift the stage distribution of tumors at the
ime of diagnosis to earlier stages, thus improving the over-
ll curability of lung cancer. Indeed, screening studies have
emonstrated a consistent stage shift with stage IA reported
n as many as 80% of participants.4
Yet controversy still exits regarding the relationship be-
ween tumor size and survival within stage IA tumors. We5
nd others6,7 have shown improved survival for stage I
umors measuring less than 2 cm, whereas others investiga-
ors have not.8,9 This issue has important implications for
ung cancer screening with CT scanning. If there is no
ifference in survival between subcentimeter tumors and
heir larger counterparts, then the rationale for using CT
canning (as opposed to chest radiographs) in detecting
mall lesions is less compelling.
In the current study, 81% of patients with resected
SCLC measuring 1 cm or less had stage IA disease and
ad a 100% lung cancer–specific survival at 5 and 10 years.
o recurrence was noted during our study period for pa-
ients with stage 1A disease. Other investigators have dem-
nstrated this superior survival as well. Martini and associ-
tes10 noted in their review of 598 patients with resected
tage I NSCLC that 35 patients had tumors measuring less
han 1 cm with 5- and 10-year survivals of 97% and 93%.
iller and colleagues11 reported on 100 patients with re-
igure 4. Disease-specific survival of patients with NSCLC mea-
uring 1 cm or less after resection, subdividing into pathologic IA
nd non-IA stage. NSCLC, non–small cell lung cancer.ected NSCLC measuring 1 cm or less, of whom 93 had n
386 The Journal of Thoracic and Cardiovascular Surgery ● Dectage I disease with a 5-year lung cancer–specific survival
f 87%. Our finding supports the concept that size does have
strong impact on survival. If CT screening does indeed
etect subcentimeter tumors and thus shifts the size and
tage distribution of tumors at diagnosis, then the impact on
ung cancer survival may be considerable. In the current
eries, 21 patients had their tumors discovered through the
LCAP screening program with low-dose CT. Eighteen
atients (86%) had stage I disease and only 1 patient had N2
isease.
However, it appears that a subset of small tumors may
ave aggressive biologic behavior. Ohta and coworkers12
ave shown that nodal micrometastases were found in 20%
f patients with adenocarcinoma measuring 1.1 to 2.0 cm in
ize and in 4 of 11 patients with tumor measuring 1.0 cm or
ess in size. In the current report of 83 patients, 16 patients
ad greater than stage IA disease, including N1 nodal me-
astasis in 4 patients and N2 metastasis in 2 patients. In
ddition, 5 patients had pleural invasion (T2 in 4, T3 in 1)
nd 5 patients had intralobar satellite lesions (T4). The
urvival in this non-IA group was significantly diminished
ompared with the IA group, mainly because of tumor
ecurrences.
There is ongoing controversy as to the extent of resection
ecessary for stage I NSCLC. The Lung Cancer Study
roup showed that for stage IA NSCLC, patients who
nderwent a limited resection (segmentectomy or wedge)
ad a higher recurrence rate and lower survival than did
hose treated by lobectomy.13 Miller and associates11 dem-
nstrated that for NSCLC measuring 1 cm or less, patients
ho underwent lobectomy had significantly improved sur-
ival and fewer recurrences than did those having limited
esection. However, other authors have suggested that lim-
ted resections are adequate treatment for early-stage dis-
ase.14-16 In our study, only 10 patients (12%) had limited
esection, mainly because of poor pulmonary reserve and/or
ssociated comorbidities. There was no significant differ-
nce in overall survival between patients with limited re-
ection and those with anatomic resection. In the 67 patients
ith stage IA tumors, 8 patients had limited resection. No
ecurrence was noted in either the limited resection or the
natomic resection group during the follow-up period. Two
imited resections were performed in the non-IA group for
2 N0 tumors with visceral pleural involvement. One pa-
ient had mediastinal recurrence that was treated with sur-
ical resection and radiotherapy and is currently alive at 12
onths without disease. Although the survival of patients
ith limited resection in this series suggests that limited
esection for 1 cm or less tumors may have equivalent
esults to lobectomy, the small sample size examined pre-
ludes any definitive conclusions. Furthermore, we were
nable to distinguish clinically, either by CT or PET scan-
ing, patients who had nodal metastasis or intralobar me-
ember 2006
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G
TSastasis before resection. Of the 4 patients with N1 nodal
etastasis and 5 patients with intralobar metastasis on final
athologic examination, only 1 patient was staged clinically
s having more advanced than IA disease before resection.
learly, a large prospective randomized trial comparing
imited resection with lobectomy is mandatory before firm
ecommendations are made favoring limited resections over
obectomy for these small tumors.
PET scanning was performed in 37 patients preopera-
ively and 15 patients had a negative result, with a false
egative rate of 41%. Among the 5 patients with pathologic
odal disease (N1 or N2) who had preoperative PET scan-
ing, PET was positive in only 1 patient’s nodal station. The
alse negative rates in detection of the primary tumor as well
s nodal metastasis are unacceptably high. Indeed, we17
ave previously reported our results of PET scanning in 64
atients with NSCLC measuring 2 cm or less. Forty-five
ercent of tumors had negative PET results, and the PET
ensitivity and specificity for nodal metastases were only
5% and 89%. Even though PET scanning has recently
ecome a routine tool in preoperative evaluations of patients
ith NSCLC, our findings suggest that PET scanning has a
ery limited role in diagnosis and staging of tumors mea-
uring 1 cm or less.
In the current series, mediastinal lymph node dissection
as performed in 74 patients, 89% of the cohort. The
ncidence of N2 nodal metastasis was 2.4%. It is doubtful
hat this low incidence of upstaging by mediastinal nodal
issection will translate into a meaningful survival benefit in
his population of patients. The Z0030 trial sponsored by the
merican College of Surgeons Oncology Group was de-
igned to determine the survival benefits of mediastinal
ymph node sampling versus complete nodal dissection at
he time of resection for NSCLC. Ideally, the results of this
rial (unpublished data) will clarify the role of mediastinal
ymph node dissection.
In this current study, no significant difference in overall
urvival was observed between the open and the thoraco-
copic lobectomy groups. The median length of stay in the
ospital for the thoracoscopic group was 4 days compared
ith 5 days in the open lobectomy group. Although there is
o published large randomized prospective series to com-
are the two approaches, various investigators have shown
hat thoracoscopic lobectomy can be done safely18 and with
ncompromised survival.19-21 For patients with subcentime-
er tumors, thoracoscopic lobectomy might be an attractive
pproach.
There are several limitations in this study. This is a
urgical series of resected NSCLC with a pathologic size of
cm or less. Our survival results should not be extrapolated
o all NSCLC tumors measuring 1 cm or less in size at the
ime of diagnosis, because patients with obvious mediasti-
al or distant metastases might not have been referred for
The Journal of Thoracicurgical evaluation. Patients who received neoadjuvant ther-
pies were also excluded in this study because the patho-
ogic size at resection might reflect treatment effects and not
he true pathologic tumor size at the time of diagnosis. The
ample size in our series is also too small to make any
efinitive recommendations on the roles of limited resection
nd mediastinal lymph node dissection in the management
f NSCLC measuring 1 cm or less in size. Large prospective
andomized studies are necessary to address these issues.
In summary, the number of NSCLC tumors measuring 1
m or less that are detected is increasing because of the
idespread use of CT and the emergence of screening
rograms. Even though the majority of tumors at resection
re in stage IA, some of these tumors may have intralobar
atellites or lymph node metastases. After surgical resection
f NSCLC tumors measuring 1 cm or less, recurrence is rare
nd long-term survival is excellent.
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iscussion
r Daniel L. Miller (Atlanta, Ga). Dr Lee, I congratulate you and
our colleagues at Cornell for your continued refinement in CT
creening and treatment of early-stage lung cancer.
I have three questions. I was impressed by your cytopatholo-
ists and interventional radiologists who achieved a diagnosis by
ne-needle aspiration on 58% of your patients with a subcentime-
er nodule, but also I was disappointed that 45% of your patients
nderwent a PET scan for a 1 cm or less nodule that was nondi-
gnostic 41% of the time. What is your institution’s current algo-
ithm for the workup of a subcentimeter pulmonary nodule?
Dr Lee. We do not generally obtain PET scans for subcenti-
eter nodules. Unfortunately, most of the patients we see in the
ffice have already had a PET scan that was ordered by the
eferring physician.
In terms of workup for subcentimeter nodules, we are very
rivileged to have a very good interventional radiologist who can
eedle a lot of these subcentimeter tumors. That is probably not
rue in other institutions. Fifty-eight percent of our patients had
issue diagnosis obtained by fine-needle aspiration before resec-
ion. As part of our workup, we examine previous x-ray films or
T scans. If the nodule is a new growth, if it has suspicious CT
ndings of solid lesion and spiculation in someone who is older
ith a smoking history, then we proceed to fine-needle aspiration.
f the nodule is not otherwise suspicious, we are inclined to
onitor the patient by CT scan in 6 months or a year. I can tell you
rom our experience that we do not routinely order PET scans to
ork these nodules up, again, because of the data indicating high
alse negative results by PET scan in detecting subcentimeter
umors.
Dr Miller. My second question is in two parts and it concerns
he histologic type of your tumors. Eighty-two percent of the
umors are either adenocarcinoma and/or bronchoalveolar carci-
oma. In your study was there any difference in survival based on
he histologic type? If so, was this difference related to nodal
nvolvement because of the histologic type?
Dr Lee. We did not see any differences in survival among the
ifferent cell types. As you mentioned, 82% of the patients had
denocarcinomas, so the number of squamous cell cancers and
arge cell cancers is small in our study. The only survival differ-
nce that we noticed was among different stages, for example,
tage IA versus non-IA. s
388 The Journal of Thoracic and Cardiovascular Surgery ● DecDr Miller. You had an outstanding 5-year and 10-year survival
or your lung cancer deaths only for stage IA. How many of those
atients had bronchoalveolar cancer? Such a high survival is very
imilar to the Japanese data.
Dr Lee. Nine patients had bronchoalveolar cancer in that
roup.
Dr Miller. And they were all in the IA group?
Dr Lee. Correct.
Dr Miller. Finally, 12% of your patients underwent a limited
esection, either a wedge or segmentectomy. You found that there
as no difference in survival based on the type of resection, and
his is probably related to the small number in that subset. What are
our institution’s current recommendations for the type of resec-
ion and the approach for these subcentimeter lung cancers, and
specially in regard to bronchoalveolar cancer?
Dr Lee. Our institution has undergone a shift in terms of doing
ore and more thoracoscopic lobectomies over the past 3 or 4
ears. The gold standard is still a lobectomy among good-risk
atients. We need a large prospective randomized study looking at
imited resection versus lobectomy to be able to fully answer that
uestion. As it stands right now, if a patient is at good risk with a
ood performance status, we offer the patient a lobectomy. Now,
f the patient has medical comorbidities or limited functional
tatus, I think it is very reasonable to offer a limited resection.
lthough we had only 2 patients with N2 metastases, we did have
patients with intralobar satellites. The disadvantage of a limited
esection is that you might miss the intralobar satellite lesions.
ntil we have the results of a large prospective randomized study,
e do not have the full answer yet. As it stands right now, we do
erform a lot of thoracoscopic lobectomies, and the only time we
erform limited resection is for very small peripheral tumors and
n someone who has poor performance status or limited pulmonary
unctions. There are also some studies suggesting that non-solid or
ronchoalveolar cancer lesions might be more amenable to limited
esection. We are looking at those questions and others with Dr
ltorki.
Dr Darroch W. O. Moores (Albany, NY). Do you have any
ata on second primaries in this long follow-up, and if the patients
ad secondary primaries, did they have second operations?
Dr Lee. We did not look specifically at second primaries. We
oted 5 recurrences overall in the patients with non-IA disease.
here were also several patients in our series who had previous
obectomies for lung cancer. They were 6 or 7 years out from the
rst operation when their current second primary tumors devel-
ped.
Dr Jack A. Roth (Houston, Tex). Dr Lee, you mentioned that
1 of your patients were in the ELCAP study, so the lesion was
icked up with screening, is that correct?
Dr Lee. Correct.
Dr Roth. Presumably the others were all incidental findings.
hat percent of those 21 patients actually had stage IA disease,
nd did you see any differences in survival in that group versus the
atients who had the lesions picked up incidentally?
Dr Lee. Eighty-six percent of that group of 21 patients had
tage I disease. There was only 1 patient in that group with N2
isease. We did not see any differences in survival between that
creened group and the remaining group.
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